Literature DB >> 23478053

Does the cetuximab plus paclitaxel combination deserve to be studied in a phase III trial?

Sebastiano Buti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23478053     DOI： 10.1200/JCO.2012.47.1219

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  1 in total

1.  Reply to S. Buti and S. Culine.

Authors:  Yu-Ning Wong; Elizabeth R Plimack; Samuel Litwin; David Vaughn; James Lee; Wei Song; Gary R Hudes
Journal:  J Clin Oncol       Date:  2013-04-20       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.